Mandeep Bhargava, MD
Cardiovascular Disease · Cleveland, OHNPI 1386757979
Payments from drug & device makers
Across 24 payments — averaging $243.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Medical Device Business Services, Inc.$1K
- Abbott$799
- Biosense Webster, Inc.$729
- Medtronic$278
- Volta Medical Inc$137
- plus $112 from 1 others
What the payments were for
- Consulting fees$1,95040%
- Travel & lodging$56012%
- Food & beverage$2,34348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $2,798 |
| Medical Device Business Services, Inc. | 1 | $1,000 |
| Abbott | 6 | $799 |
| Biosense Webster, Inc. | 5 | $729 |
| Medtronic | 2 | $278 |
| Volta Medical Inc | 1 | $137 |
| Biotronik Inc. | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,950
- Carto 3$729
- Watchman$551
- ENSITE$299
- EnSite Precision Cardiac Mapping System$202
- ENSITE PRECISION$179
- ARCTIC FRONT ADVANCE$146
- WATCHMAN FLX$140
- VX1$137
- COBALT DR MRI SURESCAN$132
How this compares
$5,853 in reported general payments places this provider in the 65th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $322,027 |
| XareltoRivaroxaban | 104 | $109,704 |
| Dofetilide | 84 | $18,622 |
| Metoprolol Succinate | 541 | $9,699 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $5,297 |
| Mexiletine Hcl | 31 | $3,329 |
| Flecainide Acetate | 99 | $3,166 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 101 | $2,174 |
| Amiodarone Hcl | 146 | $1,697 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $637 |
| Digoxin | 34 | $486 |
| Carvedilol | 57 | $435 |
| Amlodipine Besylate | 49 | $361 |
| Losartan Potassium | 24 | $304 |
| Lisinopril | 22 | $264 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Mazen HannaCleveland$1.6M
- Daniel CantillonCleveland$1.3M
- Oussama WazniCleveland$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.